Cat. No.
MABL-3801
Application
RIA, ELISA
Isotype
Engineer antibody
Species Reactivity
Human
Clone No.
B38.1
From
Recombinant Antibody
Specificity
Reactive against 80% of primary mammary tumors. Has a binding constant in the nM range.
Alternative Names
DIAR5; epithelial cell adhesion molecule; ESA; KSA; M4S1; MK-1; EGP-2; ING-1
UniProt
P16422
Immunogen
Mice were immunized with membrane-enriched fractions of human metastic mammary carcinoma cells. The spleens were extracted and fused with NS-1 to generate primary hybridoma cultures. These were screened using solid phase RIA for those which were reactive with metastic mammary tumor cells from livers but were not reactive with healthy livers.
Application Notes
Has been used to generate a human engineered monoclonal antibody (Ammons et al, 2003). B38.1 has been shown to be able to mediate antibody-dependent cytotoxicity (Robinson et al, 1991). It has undergone clinical trials as an anti-carcinoma drug (de Bono et al, 2002 and Better et al, 2002). It has also been used in ELISAs to test the reactivity of its humanised construct, ING-1, that it has an affinity in the nM range by competition assays, and it has been shown to be active in vivo (Ammons et al, 2003).
Antibody First Published
Colcher et al Monoclonal antibodies reactive with human breast cancer Proc Natl Acad Sci U S A. 1981 May;78(5):3199-203 PMID:6789331
Note on publication
Describes the formation of this antibody and others against metastic mammary carcinoma cells. Describes the characterisation of these antibodies including identifying a number of carcinoma types, other than mammary, that they are reactive against.
Size
282 μg Purified antibody.
Concentration
183 mg/ml.
Purification
Protein A affinity purified
Buffer
PBS with 0.02% Proclin 482.
Storage Recommendation
Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at - 202⁰C.
![Anti-VEGF [Bevacizumab] (MABL-](/public/static/common/images/not_adv.jpg)
